Supreme Court rules against drug patent "evergreening"

Kondro, Wayne
December 2006
CMAJ: Canadian Medical Association Journal;12/5/2006, Vol. 175 Issue 12, p1508
Academic Journal
The article reports on the ruling of the Supreme Court of Canada on a case concerning drug patent evergreening. The practice of evergreening enabled pharmaceutical companies to obtain a two-year extension on the term of patent protection. The reaction of Canadian Generic Pharmaceutical Association president Jim Keon on the ruling is presented.


Related Articles

  • Court ruling could scupper patent deal. O'Driscoll, Cath // ICIS Chemical Business;5/15/2006, Vol. 1 Issue 19, p33 

    The article reports on a ruling by the European Court of Justice that could make it harder for pharmaceutical companies to obtain patent extensions for certain products in future. The Massachusetts Institute of Technology's application for a so-called supplementary protection certificate (SPC)...

  • Drug Run. Singh, Seema // Red Herring;5/28/2007, Vol. 4 Issue 17/18, p13 

    The article explores how Indian drug companies will be affected by the April 30, 2007 ruling of the U.S. Supreme Court that makes it easier to invalidate patents and raises the threshold for obtaining patents. Indian drug companies, which produce over 22 percent of the world's generic drugs,...

  • More court rulings safeguard Lipitor. Owens, Joanna // Nature Reviews Drug Discovery;Feb2006, Vol. 5 Issue 2, p96 

    The article reports on the decisions of the courts over atorvastatin. The Court of First Instance in Madrid, Spain decided that the patents for Lipitor are valid and enforceable following a case brought about by Ratiopharm Espana against Pfizer Inc. An Andean court dismissed the Pfizer's...

  • A Supreme Challenge to Patents.  // njbiz;5/7/2007, Vol. 20 Issue 19, p14 

    The article comments on the impact of the decision of the U.S. Supreme Court to overturn patent protection in a case involving automotive gas pedals on the pharmaceutical industry in New Jersey. It states that the ruling could make it harder for the industry to extend the protected life of...

  • Eli Lilly: a reprieve for Zyprexa.  // PharmaWatch: Monthly Review;Jun2005, Vol. 4 Issue 6, p19 

    The article reports that Eli Lilly & Co. has won a key court ruling against the patent challenges to Zyprexa from three generic manufacturers. The company has now enough time to establish its two new psychiatry drugs, Strattera and Cymbalta and replace sales of Zyprexa which currently represent...

  • Final Chapter in the Glivec Saga. VAIDYA, MANASI // BioSpectrum;May2013, Vol. 11 Issue 5, p26 

    The article reports on the impact of the verdict that would prevent Novartis AG from holding a patent on its modified drug on the healthcare industry in India. Novartis India president Ranjit Shahani says that they fought the case because they believe patents safeguard innovation and encourage...

  • Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of "Secondary" Pharmaceutical Patents. Kapczynski, Amy; Park, Chan; Sampat, Bhaven // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Background: While there has been much discussion by policymakers and stakeholders about the effects of "secondary patents" on the pharmaceutical industry, there is no empirical evidence on their prevalence or determinants. Characterizing the landscape of secondary patents is important in light...

  • Teva Announces Favorable UK Court Ruling In COPAXONE(r) Patent Litigation Proceeding.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article offers information on the decision of the Great Britain High Court of Justice in favor of Teva Pharmaceutical Industries Ltd. related with patent litigation proceeding against Generics Ltd. The decision has been issued in the favor of Teva Pharmaceutical Industries Ltd. Proceedings...

  • BIG LOSSES DUE AS DRUGS COME OFF PATENT.  // H&HN: Hospitals & Health Networks;09/05/97, Vol. 71 Issue 17, p95 

    Reports on 40 drugmakers who are trying to maintain market share as some profitable patents expire by the year 2003. Strategy of other pharmaceutical company to maintain patency; Amount to lose on the expiration of patents on Pepcid and three other medication.

  • One More Flat Year, But Just Wait For 2003-2005! Rubin, Jami // Medical Marketing & Media;Jan2002, Vol. 37 Issue 1, p38 

    Focuses on the effects of patent expirations on the performance of several pharmaceutical firms. Assessment on the revenue growth of various companies; Decrease of earnings; Comparison of sales between the year 2001 and 2002.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics